2 Aug 2023 10:09
AIM WINNERS & LOSERS: Deltex plummets on return to AIM; Blancco rises
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
EVG.L Share News (EVG)
EVG Share
Price
EVG Share
News
EVG Share
Chat
EVG Share
Trades
EVG
Live RNS
EVG Share
Charts
EVG Broker
Ratings
EVG Directors
Deals
EVG Financial
Diary
EVG
Fundamentals
EVG Short
Positions
EVG
Media
EVG.L Information
- There is currently no data for EVG
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Evgen concludes patient recruitment in STEM breast cancer trial
Wed, 25th Jul 2018 14:48
(Sharecast News) - Clinical-stage drug development company Evgen Pharma has concluded patient recruitment in its STEM Phase IIa trial of SFX-01 in metastatic breast cancer, it announced on Wednesday.The AIM-traded firm described STEM as an open label trial that had regulatory approval to recruit 60 patients.Following the "favourable" interim read-out, as announced on 11 June, the principal investigator and the company's medical adviser said they believed there was sufficient evidence to conclude that the main aims of the trial - a favourable safety and tolerability profile and evidence of clinical benefit - had been successfully met.On that basis, Evgen said it had decided that there was no merit in recruiting the full number of patients allowed under the protocol.As at 24 July, 50 patients had been enrolled in the trial, with any eligible patients currently in screening also being admitted to the trial.All eligible patients would continue as per the trial protocol, and would receive SFX-01 until such point as they showed clinical progression or reached the end of the trial at six months.If they received clinical benefit for the full duration of the trial, Evgen said that like all other patients in the trial, they would be eligible for entry into the compassionate use programme.On that basis, the final readout would occur around the end of the calendar year, which would include details of the safety, tolerability and the clinical benefit rate observed across all patients."The STEM trial is an exploratory trial that was designed to demonstrate safety and tolerability with long-term exposure to SFX-01 and to provide evidence that it has anti-tumour activity after failure of at least one and up to three prior hormone therapies," said principal investigator Dr Sacha Howell."With these objectives in mind, we have sufficient evidence to believe that SFX-01 warrants further investigation through the conduct of a randomised placebo-controlled trial."Dr Stephen Franklin, CEO of Evgen, added that the company was "excited" that so far, the data from its exploratory STEM trial supported further clinical evaluation of SFX-01, with the board "looking forward" to the final read-out around the end of the calendar year."The next step is likely to be a placebo-controlled trial, testing SFX-01 in combination with second-line hormone therapy in patients that have failed on CDK4/6 inhibitors."This is the initial setting for which we wish to see SFX-01 approved in metastatic breast cancer."
More News
13 Jul 2023 15:58
UK shareholder meetings calendar - next 7 days
| Friday 14 July | |
| Templeton Emerging Markets Investment Trust PLC | AGM |
| Monday 17 July | |
| All ThingsConsidered Group PLC | AGM |
| Tower Resources PLC | AGM |
| Tuesday 18 July | |
| Alkemy Capital Investments PLC | AGM |
| Bloomsbury Publishing PLC | AGM |
| CT Property Trust Ltd | GM re takeover by LondonMetric Property |
| e-Therapeutics PLC | AGM |
| MobilityOne Ltd | EGM re Tete planned JV deadline extension |
| SmartSpace Software PLC | AGM |
| Strategic Minerals PLC | AGM |
| Wynnstay Properties PLC | AGM |
| Wednesday 19 July | |
| Berkeley Energia Ltd | AGM |
| Caledonian Trust PLC | AGM |
| DG Innovate PLC | AGM |
| Experian PLC | AGM |
| HICL Infrastructure PLC | AGM |
| Mind Gym PLC | AGM |
| Sportech PLC | GM re share capital restructure |
| Triple Point Income VCT PLC | AGM |
| Thursday 20 July | |
| ACG Acquisition Co Ltd | EGM re acquisition of the Atlantic Nickel |
| Big Yellow Group PLC | AGM |
| CT UK High Income Trust PLC | AGM |
| Evgen Pharma PLC | AGM |
| FD Technologies PLC | AGM |
| Fuller, Smith & Turner PLC | AGM |
| GB Group PLC | AGM |
| Halma PLC | AGM |
| Intermediate Capital Group PLC | AGM |
| International Distributions Services PLC | AGM |
| Fidelity China Special Situations PLC | AGM |
| Johnson Matthey PLC | AGM |
| Kingspan Group PLC | EGM re delisting |
| Pennon Group PLC | AGM |
| Premier Foods PLC | AGM |
| Premier Miton Group PLC | AGM |
| Qinetiq Group PLC | AGM |
| SSE PLC | AGM |
| TR Property Investment Trust PLC | AGM |
| VP PLC | AGM |
| Weiss Korea Opportunity Fund Ltd | AGM |
| Copyright 2023 Alliance News Ltd. All Rights Reserved. | |
27 Jun 2023 10:17
AIM WINNERS & LOSERS: Unbound shares drop as calls off sales process
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.
Read more27 Jun 2023 10:01
Evgen Pharma's SFX-01 has positive effects for treating a rare cancer
(Alliance News) - Evgen Pharma PLC on Tuesday said its lead asset SFX-01 has radio-sensitising effects in vivo in a form of soft tissue sarcoma, as part of its research partnership with Sapienza University of Rome.
Read more19 Jun 2023 10:05
Evgen collaborator receives grant from KWF Dutch Cancer Society
(Alliance News) - Evgen Pharma PLC on Monday said its collaborator at the Erasmus University Medical Center in Rotterdam has received notice of a grant from KWF Dutch Cancer Society.
Read more7 Jun 2023 11:41
Evgen Pharma confident amid Stalicla deal; CFO Moulson to retire
(Alliance News) - Evgen Pharma PLC on Wednesday reported a widened annual loss and said its Chief Financial Officer Richard Moulson will retire in late July.
Read more31 May 2023 15:46
UK earnings, trading statements calendar - next 7 days
| Thursday 1 June | |
| Auto Trader Group PLC | Full Year Results |
| Dr Martens PLC | Full Year Results |
| Pennon Group PLC | Full Year Results |
| Trinity Exploration & Production PLC | Full Year Results |
| Friday 2 June | |
| TR Property Investment Trust PLC | Full Year Results |
| Nostrum Oil & Gas PLC | Full Year Results |
| Monday 5 June | |
| Celadon Pharmaceuticals PLC | Full Year Results |
| Hercules Site Services PLC | Half Year Results |
| Itaconix PLC | Full Year Results |
| Sirius Real Estate Ltd | Full Year Results |
| ValiRx PLC | Full Year Results |
| Verici Dx PLC | Full Year Results |
| Tuesday 6 June | |
| British American Tobacco PLC | Trading Statement |
| Chemring Group PLC | Half Year Results |
| Ferguson PLC | Q3 Results |
| Gooch & Housego PLC | Half Year Results |
| Jadestone Energy PLC | Full Year Results |
| N Brown Group PLC | Full Year Results |
| NewRiver REIT PLC | Full Year Results |
| Oxford Metrics PLC | Half Year Results |
| Paragon Banking Group PLC | Half Year Results |
| Speedy Hire PLC | Full Year Results |
| Warehouse REIT PLC | Full Year Results |
| Wednesday 7 June | |
| discoverIE Group PLC | Full Year Results |
| Evgen Pharma PLC | Full Year Results |
| LXi REIT PLC | Full Year Results |
| Ramsdens Holdings PLC | Half Year Results |
| Residential Secure Income PLC | Half Year Results |
| Vp PLC | Full Year Results |
| Copyright 2023 Alliance News Ltd. All Rights Reserved. | |
22 Mar 2023 11:10
IN BRIEF: Evgen Pharma shares up as pharmacokinetic data announced
Evgen Pharma PLC - Cheshire, England-based clinical stage drug development company focusing on sulforaphane-based medicines - Presents top line pharmacokinetic data for its placebo-controlled, dose-escalating, randomised Phase I/Ib clinical trial. Says the study is aimed to provide further insight into the pharmacokinetic and pharmacodynamic characteristics of the new enteric coated tablet formulation of the company's lead asset SFX-01, as well as investigating how sulforaphane released from the tablet engages with targets of interest. Says SFX-01 shows no serious adverse effects and the study is on schedule for full reporting in the second quarter.
Read more22 Mar 2023 10:30
AIM WINNERS & LOSERS: Pathfinder finds way forward in Mozambique
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.
Read more16 Mar 2023 16:35
Evgen notes evidence of radiosensitisation by SFX-01 in cancer cells
(Alliance News) - Evgen Pharma PLC said on Thursday it had found further evidence of radiosensitisation by SFX-01 in sarcoma cells.
Read more13 Mar 2023 12:18
SUMMARY: London listings with exposure to Silicon Valley Bank
(Alliance News) - The following is a round-up of updates on exposure to Silicon Valley Bank by London-listed companies, issued on Monday and not separately reported by Alliance News:
Read more25 Jan 2023 10:40
Evgen Pharma completes dosing of clinical trial for SFX-01 tablet
(Alliance News) - Evgen Pharma PLC on Wednesday said it completed the dosing of all three cohorts of the phase 1/1b clinical trial of its SFX-01 tablet formulation.
Read more8 Dec 2022 13:57
Evgen Pharma loss, operating expenses widen; SFX-01 study on schedule
(Alliance News) - Evgen Pharma PLC on Thursday said interim loss widened, but noted the healthy volunteer study of its SFX-01 formulation remains on schedule.
Read more16 Nov 2022 16:11
Evgen Pharma starts clinical trial of new SFX-01 tablet
(Alliance News) - Evgen Pharma PLC said on Wednesday it had started a randomised, placebo-controlled clinical trial of its new SFX-01 tablet.
Read more16 Nov 2022 14:05
Evgen Pharma doses first volunteers in SFX-01 trial
(Sharecast News) - Clinical-stage drug developer Evgen Pharma has dosed the first group of healthy volunteers in its placebo-controlled, dose-escalating, randomised phase 1 and 1b clinical trial, it announced on Wednesday.
Read more